XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2

Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

Segment information for the three months ended March 31, 2024 and 2023 is as follows (in thousands):

		Three Months Ended March 31, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	27,172			$	—			$	—			$	27,172
Cost of revenues			979				—				—				979
Gross profit			26,193				—				—				26,193
Operating expenses excluding cost of revenues:
Selling and marketing			12,542				—				—				12,542
Research and development			2,009				173				—				2,182
General and administrative			2,257				1,141				—				3,398
Total operating expenses excluding cost of revenues			16,808				1,314				—				18,122
Income (loss) from operations		$	9,385			$	(1,314	)		$	—			$	8,071
Supplemental disclosure of stock-based compensation expense:
General and administrative		$	—			$	11			$	—			$	11
Stock-based compensation total		$	—			$	11			$	—			$	11

		March 31, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	109,347			$	11,750			$	913			$	122,010

The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.

		Three Months Ended March 31, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	217			$	14			$	—			$	231

		Three Months Ended March 31, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	24,931			$	—			$	—			$	24,931
Cost of revenues			1,125				—				—				1,125
Gross profit			23,806				—				—				23,806
Operating expenses excluding cost of revenues:
Selling and marketing			12,768				—				—				12,768
Research and development			2,635				—				—				2,635
General and administrative			1,722				—				17				1,739
Total operating expenses excluding cost of revenues			17,125				—				17				17,142
Income (loss) from operations		$	6,681			$	—			$	(17	)		$	6,664
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation total		$	—			$	—			$	—			$	—

		December 31, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	101,761			$	13,865			$	913			$	116,539

The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.

		Three Months Ended March 31, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	1,742			$	—			$	—			$	1,742

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration